GENFIT: First Half-Year 2020 Financial Report and New Corporate Strategy

NEXT STORY
Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory Gout
PREV STORY
G1 Therapeutics Announces Chief Executive Officer Succession Plan
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)

author_avatar
NASDAQ Market News

Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting

author_avatar
NASDAQ Market News

Advanced Wound Care Market Research Report by Product, by Application, by End User – Global Forecast to 2025 – Cumulative Impact of COVID-19

author_avatar
NASDAQ Market News